Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epidemiology of chronic red-cell transfusion recipients in Sweden and Denmark-a 10 year follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Iron deficiency and preoperative anaemia in patients scheduled for elective hip- and knee arthroplasty - an observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. New drug candidates for depression - a nationwide population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pentaisomaltose, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34+ Cells in Immunodeficient NSG Mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Restless legs syndrome is associated with major comorbidities in a population of Danish blood donors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Continuation of lithium after a diagnosis of chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND OBJECTIVES: Daratumumab binds CD38 on red blood cells causing interference with indirect antiglobulin tests. Dithiothreitol is used to eliminate interference allowing detection of alloantibodies. Haemolysis is observed during storage of dithiothreitol-treated antibody identification panel cells. The objective of this study was to develop a modified method for dithiothreitol treatment to reduce the haemolysis during 33 days of storage and still be able to eliminate daratumumab interference.

MATERIALS AND METHODS: Panel cells were treated with various volumes of 0·2 m dithiothreitol supplied by various manufacturers. Haemolysis Index of dithiothreitol-treated and untreated panel cells was measured and compared on days 1, 15 and 33. Antibody screening tests with dithiothreitol-treated screening cells were performed on samples from 15 daratumumab-treated patients (dose 16 mg/kg) and 34 patients with known alloantibodies. Antibody identifications with dithiothreitol-treated panel cells were performed on seven additional known alloantibodies.

RESULTS: Dithiothreitol treatment with a ratio of 30:25 (red blood cells:dithiothreitol) showed the same degree of haemolysis as with untreated panel cells. Daratumumab interference was eliminated in all 15 samples from daratumumab-treated patients. Twenty-six of 34 alloantibodies were detected, and all seven additional alloantibodies were identified using the modified dithiothreitol treatment. Eight alloantibodies within the Kell system were negative. No decrease in the reaction strength was observed during the 33-day storage period.

CONCLUSION: The modified dithiothreitol method was able to reduce haemolysis during storage and to detect and identify alloantibodies in the presence of daratumumab.

Original languageEnglish
JournalVox Sanguinis
Volume113
Issue number7
Pages (from-to)686-693
Number of pages8
ISSN0042-9007
DOIs
Publication statusPublished - Oct 2018

    Research areas

  • Antibodies, Monoclonal/adverse effects, Blood Preservation/methods, Dithiothreitol/pharmacology, Erythrocytes/drug effects, Humans, Serologic Tests/methods

ID: 57805264